News und Analysen
![QIAGEN launches QIAstat-Dx test kit for detection of SARS-CoV-2 coronavirus in Europe following CE marking](/assets/news/news8-29d1d55c755b03e328399113b5bdd004223f995e95194ba5ee80af9da39a41e3.png)
QIAGEN launches QIAstat-Dx test kit for detection of SARS-CoV-2 coronavirus in Europe following CE marking
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that it has obtained CE marking for its newly developed QIAstat-Dx Respiratory SARS-CoV-2 Panel test to be sold as an in vitro
![Agilent Technologies Announces Cash Dividend of 18 Cents Per Share](/assets/news/news6-ad07925a95156ae03dbe17caf44a9dc29f254ff2c2a42c7678d35288ad55cec8.png)
Agilent Technologies Announces Cash Dividend of 18 Cents Per Share
Agilent Technologies Inc. (NYSE: A) today announced that a quarterly dividend of 18 cents per share of common stock will be paid on April 22, 2020, to all shareholders of record as of the close of
![Pfizer Postpones Investor Day Scheduled for March 31, 2020 Due to Coronavirus Concerns](/assets/news/news5-af8c677c86bb4b693f58afef33877e6f798ff0d7e2b4fa69b6e89960549b5ee6.png)
Pfizer Postpones Investor Day Scheduled for March 31, 2020 Due to Coronavirus Concerns
Pfizer Inc. (NYSE: PFE) announced today that given the unique circumstances of the COVID-19 pandemic and Pfizer’s responsibility to prioritize the health and safety of colleagues and invited
![Pfizer Announces Positive Top-Line Results from Third Phase 3 Trial of Abrocitinib for Moderate to Severe Atopic Dermatitis, Which Showed Improvements in Skin Clearance, Disease Extent and Severity, and Itch](/assets/news/news4-fce0efe65d8ba787508ef718c0a20bed51e468dbc656c188c43e13f15b4a4f53.png)
Pfizer Announces Positive Top-Line Results from Third Phase 3 Trial of Abrocitinib for Moderate to Severe Atopic Dermatitis, Which Showed Improvements in Skin Clearance, Disease Extent and Severity, and Itch
Pfizer Inc. (NYSE:PFE) announced today that JADE COMPARE (B7451029) met its co-primary efficacy endpoints. The Phase 3 study evaluated the safety and efficacy of abrocitinib, an investigational
![Pfizer Announces Top-Line Results from Phase 3 Study of 20-Valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-Naïve Adults Aged 18 Years or Older](/assets/news/news3-3816cd3656012f9a06bae00ff06108b383643da017a8247fff474f84ea8a7c5a.png)
Pfizer Announces Top-Line Results from Phase 3 Study of 20-Valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-Naïve Adults Aged 18 Years or Older
Pfizer Inc. (NYSE:PFE) today announced top-line results from one of its Phase 3 studies (NCT03760146), which evaluated the safety and immunogenicity of its 20-valent pneumococcal conjugate vaccine
![Sandra Suarez-Sharp Joins Simulations Plus to Lead Regulatory Strategies Team](/assets/news/news1-f26f2455ece0c3cbea64441818e795358cadddddb27e796f883ae2bd06f66139.png)
Sandra Suarez-Sharp Joins Simulations Plus to Lead Regulatory Strategies Team
Simulations Plus, Inc. (Nasdaq: SLP), the leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemicals, and consumer goods industries, today announced that
![IMV Inc. Establishes At-the-Market Facility](/assets/news/news17-d49b9ce9c87babddea210274f0f8d00a1cf706146ef6382020cc7ece83b76f6c.png)
IMV Inc. Establishes At-the-Market Facility
IMV Inc. (TSX: IMV; NASDAQ: IMV) (the "Company" or “IMV”), a clinical-stage biopharmaceutical company, today announced that it has entered into an equity distribution agreement, dated March 18
![IMV Inc. Launches Plans to Advance Clinical Development of a Vaccine Candidate Against COVID-19](/assets/news/news5-af8c677c86bb4b693f58afef33877e6f798ff0d7e2b4fa69b6e89960549b5ee6.png)
IMV Inc. Launches Plans to Advance Clinical Development of a Vaccine Candidate Against COVID-19
IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company (the “Company” or “IMV”), today announced that it is advancing the clinical development of a DPX-based vaccine candidate
![Aurinia Announces AURORA Phase 3 Clinical Data for Voclosporin in Lupus Nephritis to be Presented at National Kidney Foundation 2020 Spring Clinical Meetings](/assets/news/news4-fce0efe65d8ba787508ef718c0a20bed51e468dbc656c188c43e13f15b4a4f53.png)
Aurinia Announces AURORA Phase 3 Clinical Data for Voclosporin in Lupus Nephritis to be Presented at National Kidney Foundation 2020 Spring Clinical Meetings
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company focused on advancing voclosporin in multiple indications, today
![Quidel Receives Emergency Use Authorization for Molecular COVID-19 Diagnostic Assay](/assets/news/news11-1ebbf8540812dc8f080ecfeb67ce19c492651a7c439bd800cec2630c3a04a840.png)
Quidel Receives Emergency Use Authorization for Molecular COVID-19 Diagnostic Assay
Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that Quidel has
![QIAGEN Dramatically Ramping Up Global Production Capacity for RNA Extraction Kits for Use in Detection of SARS-CoV-2 Coronavirus](/assets/news/news10-be520e400538f920c1970757e43cd0aa35625c1095be243829bb7a152346bd95.png)
QIAGEN Dramatically Ramping Up Global Production Capacity for RNA Extraction Kits for Use in Detection of SARS-CoV-2 Coronavirus
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced plans to dramatically ramp up global production capacity of RNA extraction kits that are used as part of workflows around the
![Agilent Technologies to Adjourn Annual Meeting Until April 17, 2020](/assets/news/news9-b4ba75b613b80e3d047ded18f34335e7f81348578b67aee3f1469440916c031e.png)
Agilent Technologies to Adjourn Annual Meeting Until April 17, 2020
Agilent Technologies, Inc. (NYSE: A) today announced plans to adjourn its annual meeting of stockholders, originally scheduled to be held March 18, 2020, due to public health considerations
![NANOBIOTIX 2019 Annual Results](/assets/news/news8-29d1d55c755b03e328399113b5bdd004223f995e95194ba5ee80af9da39a41e3.png)
NANOBIOTIX 2019 Annual Results
Regulatory News:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200317005789/en/
Pipeline (Graphic: NANOBIOTIX)
![Humana Foundation Donates $500,000 in Support of Coronavirus Pandemic Relief and Recovery Efforts](/assets/news/news11-1ebbf8540812dc8f080ecfeb67ce19c492651a7c439bd800cec2630c3a04a840.png)
Humana Foundation Donates $500,000 in Support of Coronavirus Pandemic Relief and Recovery Efforts
The Humana Foundation, philanthropic arm of Humana Inc. (NYSE: HUM), announced today it will provide $500,000 in support of coronavirus (COVID-19) relief and recovery efforts, partnering with three
![Pfizer Invites Public to View and Listen to Webcast of April 28 Conference Call with Analysts](/assets/news/news11-1ebbf8540812dc8f080ecfeb67ce19c492651a7c439bd800cec2630c3a04a840.png)
Pfizer Invites Public to View and Listen to Webcast of April 28 Conference Call with Analysts
Pfizer Inc. (NYSE:PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EDT on Tuesday, April 28, 2020. The purpose
![Novus Therapeutics Reports Fourth Quarter and Full-Year 2019 Financial Results](/assets/news/news5-af8c677c86bb4b693f58afef33877e6f798ff0d7e2b4fa69b6e89960549b5ee6.png)
Novus Therapeutics Reports Fourth Quarter and Full-Year 2019 Financial Results
Novus Therapeutics, Inc. (NASDAQ: NVUS), a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat, today announced financial
![Aurinia Pharmaceuticals Establishes U.S. Commercial Operations Center in Rockville, Maryland](/assets/news/news2-a19c21d90ec8043c932052617f43da76ea8e48ecd096318e237ea24d69a5c8b8.png)
Aurinia Pharmaceuticals Establishes U.S. Commercial Operations Center in Rockville, Maryland
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company focused on advancing voclosporin in multiple indications, today
![Pfizer and BioNTech to Co-Develop Potential COVID-19 Vaccine](/assets/news/news14-e52b56a6adda780de8ab40d75cabe14dcfa77fc9676e986401297a29e68c991e.png)
Pfizer and BioNTech to Co-Develop Potential COVID-19 Vaccine
Pfizer Inc. (NYSE: PFE, “Pfizer”) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) today announced that the companies have agreed to a letter of intent regarding the co-development and distribution
![American Renal Associates Holdings, Inc. Announces Fourth Quarter 2019 Results](/assets/news/news9-b4ba75b613b80e3d047ded18f34335e7f81348578b67aee3f1469440916c031e.png)
American Renal Associates Holdings, Inc. Announces Fourth Quarter 2019 Results
American Renal Associates Holdings, Inc. (NYSE: ARA) (the “Company”), a leading kidney care and dialysis provider focused on partnering with local nephrologists, today announced financial and
![Drägerwerk: Die Bundesregierung redet ein großes Wörtchen mit!](/assets/news/news14-e52b56a6adda780de8ab40d75cabe14dcfa77fc9676e986401297a29e68c991e.png)
Drägerwerk: Die Bundesregierung redet ein großes Wörtchen mit!
Es war der nächste schwarze Montag an den Börsen – eine der ganz wenigen Ausnahmeerscheinungen ist die Aktie von Drägerwerk (WKN: 555060). Der unscheinbare Titel aus dem SDAX ging heute mit einem
![Geratherm: Explosion nach Corona-News!](/assets/news/news2-a19c21d90ec8043c932052617f43da76ea8e48ecd096318e237ea24d69a5c8b8.png)
Geratherm: Explosion nach Corona-News!
Die explosivsten Wertsteigerungen verzeichnen in Corona-Zeiten Aktien von Unternehmen, deren Präparate oder Produkte zur Eindämmung oder Bekämpfung des COVID-19-Virus dienen. Die heutige News von Ge
![Premier Inc. Survey: More Than Two-Thirds of Senior Living Facilities Say They Can’t Access Personal Protective Equipment Needed for COVID-19 Containment Plans](/assets/news/news10-be520e400538f920c1970757e43cd0aa35625c1095be243829bb7a152346bd95.png)
Premier Inc. Survey: More Than Two-Thirds of Senior Living Facilities Say They Can’t Access Personal Protective Equipment Needed for COVID-19 Containment Plans
Premier Inc. (NASDAQ: PINC), a leading healthcare improvement company, today released survey results finding that more than two-thirds of senior living facilities in the United States cannot obtain
![Agilent Introduces CrossLab Connect Services for Lab-wide Asset Monitoring](/assets/news/news16-82a218458f0e15ae617f9186b258dfd3add112716106c6ee3cbb48563ccdef52.png)
Agilent Introduces CrossLab Connect Services for Lab-wide Asset Monitoring
Agilent Technologies Inc. (NYSE: A) announced today an extension to its digital lab capabilities with Agilent CrossLab Asset Monitoring, an advanced service for laboratories seeking increased
![Aurinia Pharmaceuticals Initiates Rolling Submission of a New Drug Application to the U.S. Food and Drug Administration for Voclosporin in the Treatment of Lupus Nephritis](/assets/news/news14-e52b56a6adda780de8ab40d75cabe14dcfa77fc9676e986401297a29e68c991e.png)
Aurinia Pharmaceuticals Initiates Rolling Submission of a New Drug Application to the U.S. Food and Drug Administration for Voclosporin in the Treatment of Lupus Nephritis
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company focused on advancing voclosporin in multiple indications
![Lysogene Announces the Date of Its 2020 General Shareholders’ Meeting and Amends Its Financial Calendar](/assets/news/news12-a6c8e663da6f66e4f8b76885d84b91bc276bfd92fd8727e9ade1f1d9f4df9b67.png)
Lysogene Announces the Date of Its 2020 General Shareholders’ Meeting and Amends Its Financial Calendar
Regulatory News:
Lysogene (FR0013233475 – LYS) (Paris:LYS) today announced the amendment of its corporate agenda* for 2020. The annual results for 2019 will be issued on 22 April 2020 instead of